---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-016371"
form_type: "8-K"
ticker: null
cik: "0001838821"
company_name: "ARYA Sciences Acquisition Corp IV"
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:32:19.690656+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq adds annual meeting deficiency as separate delisting basis for ARYA; hearing April 25

## Summary
- Additional Nasdaq delisting notice for failure to hold annual meeting within 12 months of FYE (Rule 5620(a)).
- Hearing before Nasdaq Panel scheduled April 25, 2024 to consider both delisting bases.
- Trading previously stayed; no assurance of continued listing on Nasdaq Capital Market.
- Proposed business combination with Adagio Medical at risk if delisting occurs.

## SEC filing metadata
- accession: 0001140361-24-016371
- form_type: 8-K
- cik: 0001838821
- company_name: ARYA Sciences Acquisition Corp IV
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1838821/000114036124016371/0001140361-24-016371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1838821/000114036124016371/ef20025513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-016371
- JSON: https://secwatch.observer/filing/0001140361-24-016371.json
- Plain text: https://secwatch.observer/filing/0001140361-24-016371.txt

## Key facts
- Listing & Compliance Notices
  ARYA Sciences Acquisition Corp IV received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5620(a)
  source text: March 26, 2024, ARYA received an additional and separate notice from the staff of the Listing Department of Nasdaq formally notifying ARYA that the deficiency under Nasdaq Listing Rule 5620(a) serves as an additional and separate basis for delisting and that the Panel will consider such additional matter at ARYA’s upcoming hearing (currently scheduled on April 25, 2024) to render a determination on ARYA’s continued listing on The Nasdaq Capital Market. There can be no assurance that ARYA will be able to satisfy Nasdaq’s continued listing requirements, obtain a favorable determination of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1838821/000114036124016371/0001140361-24-016371-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.